Goldman Sachs
IRLA

Goldman Sachs’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Goldman Sachs’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25
Closed -$458K – 6657
2021
Q3 		$458K Hold
25
– – ﹤0.01% 5249
2021
Q2 		$265K Buy
+25
New +$210K ﹤0.01% 5594

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's IRLA Position: Q2 2026 in Review

Goldman Sachs sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 80 shares — an estimated $1.63K sold.

Goldman Sachs first reported a position in IRLA in Q2 2019 and held it in 15 quarters. The position peaked at $3.74M in Q3 2021. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Goldman Sachs reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 80 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $1.63K.
  • Goldman Sachs first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 15 quarters.
  • Goldman Sachs's IRulya Therapeutics Inc. Common Stock position peaked at $3.74M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.